BD (Becton, Dickinson and Company), a global leader in medical technology, has announced the initiation of the first pharma-sponsored clinical trial utilizing the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologic drugs. This trial marks a significant step towards enhancing patient care by potentially converting infused medications that require hospital visits to more convenient self-injection options at home. The BD Libertas™ Wearable Injector, which has been validated through over 50 pre-clinical and clinical studies conducted by BD, offers a fully mechanical, patient-ready design with a straightforward "peel, stick and click" mechanism. The results of this trial have not yet been presented. For further information on the BD Libertas™ Wearable Injector and its capabilities, interested parties are directed to visit BD's official website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。